- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin's Pithampur Unit-3 facility recently underwent a US FDA inspection, which concluded with three observations on a Form 483. The company has announced it will address these findings quickly and work with the FDA to resolve them within the given timeframe, reinforcing its dedication to CGMP quality standards. This is a key operational development. Investors should watch how fast these issues are resolved, as it impacts the facility's standing for US market supplies, an important factor for future business prospects.